VISTIDE
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VISTIDE by Gilead Sciences is clinical pharmacology pharmacokinetics vistide must be administered with probenecid. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids). First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISTIDE (cidofovir) is an intravenous nucleotide analog antiviral approved in 1996 for treating cytomegalovirus (CMV) retinitis in immunocompromised patients, particularly those with HIV/AIDS. The drug works by inhibiting viral DNA polymerase and is administered as an IV solution requiring careful dosing and hydration protocols.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; brand team likely focused on retention and managed decline rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY PHARMACOKINETICS VISTIDE must be administered with probenecid. The pharmacokinetics of cidofovir, administered both without and with probenecid, are described below. The pharmacokinetics of cidofovir without probenecid were evaluated in 27 HIV-infected patients with or without…
Worked on VISTIDE at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.